BioNTech/BMS Pumitamig Hits 57–68% Response Rates in First-Line NSCLC at ASCO 2026

BioNTech and Bristol Myers Squibb presented interim Phase 2 data from the global Phase 2/3 ROSETTA Lung-02 trial evaluating pumitamig (BNT327/BMS-986545), BioNTech's PD-L1×VEGF-A bispecific immunotherapy, plus chemotherapy in previously untreated advanced non-small cell lung cancer (NSCLC). At an April 13, 2026 data cutoff (40 response-evaluable patients, ~9-month median follow-up), the combination produced a confirmed objective response rate of 57.1% in non-squamous NSCLC and 68.4% in squamous NSCLC, with a 100% disease control rate across both histologies; responses were observed regardless of PD-L1 expression (47.6%–100% ORR by TPS subgroup). The data were presented as a rapid oral presentation (abstract #8513) on May 30, 2026 at the ASCO Annual Meeting in Chicago. Pumitamig is a centerpiece of BioNTech's late-stage immuno-oncology pipeline, which the company is advancing alongside its mRNA neoantigen vaccine programs (BNT111, BNT116, BNT122/autogene cevumeran) as part of a broader push toward combination cancer immunotherapy.